Stoke Therapeutics, Inc. (STOK)

NMS – Цена в реальном времени. Валюта: USD

32.49

-0.15 (-0.46%)

При закрытии: May 12, 2026, 4:00 PM EDT

09.05.2026

Stoke Therapeutics Q1 Earnings Call Highlights

Stoke Therapeutics NASDAQ: STOK said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label extension data, while the company remains on track to complete enrollment in its pivotal Phase 3 EMPEROR study in June.

08.05.2026

Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript

08.05.2026

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to earnings of $1.9 per share a year ago.

07.05.2026

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the first quarter ended March 31, 2026, and announced new 4-year longitudinal d.

01.05.2026

Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome

I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a rolling NDA submission in the first half of 2027. Three-year open-label data show durable seizure reduction and functional improvement, supporting disease-modifying potential for zorevunersen.

16.04.2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on April 15, 2026, it granted stock options to purchase an aggregate of 129,565 shares of common stock to fourt.

08.04.2026

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, Ap.

Видео

No Data

There is no data to display

Пресс-релизы

07.05.2026

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

16.04.2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on April 15, 2026, it granted stock options to purchase an aggregate of 129,565 shares of common stock to fourt.

07.04.2026

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. “Clare brings more than three decades of industry experience,.

17.03.2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on March 16, 2026, it granted stock options to purchase an aggregate of 58,650 shares of common stock to six ne.

Stoke Therapeutics, Inc. (STOK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Q1 Earnings Call Highlights

Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Видео

No Data

Пресс-релизы

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Q1 Earnings Call Highlights

Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Видео

No Data

Пресс-релизы

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Search stocks

Stoke Therapeutics, Inc. (STOK)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Q1 Earnings Call Highlights

Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Видео

No Data

Пресс-релизы

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Q1 Earnings Call Highlights

Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

Видео

No Data

Пресс-релизы

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)